On May 6, 2025, the Global Initiative For Asthma (GINA) published the 2025 update to their Global Strategy for Asthma ...

AstraZeneca’s Trixeo Aerosphere approved in UK as first inhaled respiratory medicine using next-generation propellant with near-zero GWP ...

The formoterol approval reaffirms the Ritedose commitment to patient well-being and access to critical medicines. Backed by its Blow-Fill-Seal technology and a robust pipeline of inhalation and ...

Breztri Aerosphere, which was approved for chronic obstructive pulmonary disorder (COPD) in 2020, is a fixed-dose combination of the corticosteroid budesonide, the LABA formoterol fumarate and the ...

In the present cohort study, the researchers compared the effectiveness and safety of two single-inhaler triple therapies for COPD — budesonide-glycopyrrolate-formoterol (administered twice ...

Long-awaited joint UK guidelines for asthma have been finalised, overhauling recommendations to GPs for diagnostics and treatment of the condition. In June, draft guidance published by NICE, BTS and ...

The independent guideline committee looked at evidence which showed using the combined ICS and formoterol inhalers when required led to people suffering fewer severe asthma attacks. As part of the ...

Comparators included inhaled corticosteroids (ICS) with formoterol, ICS with short-acting beta agonists (SABA), SABA alone and formoterol alone. “Their comparative efficacy is important because ...

ICS-formoterol and ICS-SABA were not associated with an increased risk for serious adverse events compared with SABA alone (high and moderate certainty, respectively).

While ICS-formoterol was likely associated with lower risks of severe complications compared to ICS-SABA, it may not lead to significant improvements in asthma symptoms or quality of life.